BIA
XENE icon

Bell Investment Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Bell Investment Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.04K Hold
100
– – ﹤0.01% 905
2026
Q1 		$5.82K Hold
100
– – ﹤0.01% 900
2025
Q4 		$4.48K Buy
100
+89
+809% +$3.74K ﹤0.01% 1013
2025
Q3 		$442 Hold
11
– – ﹤0.01% 1803
2025
Q2 		$345 Hold
11
– – ﹤0.01% 1820
2025
Q1 		$370 Sell
11
-88
-89% -$3.34K ﹤0.01% 1834
2024
Q4 		$3.88K Buy
99
+35
+55% +$1.45K ﹤0.01% 1047
2024
Q3 		$2.52K Hold
64
– – ﹤0.01% 1254
2024
Q2 		$2.5K Buy
64
+34
+113% +$1.36K ﹤0.01% 1260
2024
Q1 		$1.29K Buy
+30
New +$1.38K ﹤0.01% 1522

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Bell Investment Advisors's XENE Position: Q2 2026 in Review

Bell Investment Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 100 shares worth $6.04K. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Bell Investment Advisors first reported a position in XENE in Q1 2024 and has held it in 10 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Bell Investment Advisors held 100 shares of Xenon Pharmaceuticals worth $6.04K as of Q2 2026.
  • Bell Investment Advisors left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #905 holding.
  • Bell Investment Advisors first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.